Weight loss therapeutics Market Size,Growth, Share, Industry, Forecast and outlook (2024-2031)

Furthermore, the numerous lifestyle changes, together with rising demand for treatment at the point of care, are driving up the weight loss therapeutics market size. Due to the expansion of research in these fields, the market is seeing an increase in demand from North American regions. With significant competitors like F Hoffmann-la Roche Ltd, Altimmune, Viking Therapeutics, and others actively operating in the market, the competitive struggle is escalating the weight loss therapeutics market growth.

Download Free PDF Sample -https://www.datamintelligence.com/download-sample/weight-loss-therapeutics-market

Market Dynamics

The rising incidence of chronic disorders, together with increasing demand for treatment at the point of care, recent developments in therapeutics, sruging clinical trials and novel product launch, are likely to fuel global weight loss therapeutics market size expansion throughout the course of the forecast period.The Vikings Therapeutics is creating a novel class of dual agonists for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptors in an effort to treat numerous metabolic illnesses, including obesity, NASH, and a few uncommon diseases. The medication candidate in its primary clinical study is VK2735. Data from a Phase 1 trial assessing VK2735 (subcutaneously dosed) for metabolic diseases were released in the first quarter of 2023, and they showed a promising safety and tolerability profile as well as encouraging signals of therapeutic efficacy.

To Know More Insights - https://www.datamintelligence.com/research-report/weight-loss-therapeutics-market

Segment Analysis

Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies and online pharmacies. Due to the rise in demand for infectious diseases and cardiovascular diseases, weight loss therapeutics is the most rapidly expanding industry. Due to the increasing rising number of chronic disorders associated with obesity, the hospital pharmacies segment held the greatest market share in the global weight loss therapeutics market. Diabetes and heart disease are both greatly accelerated by obesity. Key treatment objectives in the treatment of obesity and its comorbidities, particularly type 2 diabetes, are weight loss and maintenance. Unfortunately, some hormonal changes brought on by weight reduction can promote weight return and prevent continued weight loss. The elements of contraindications, side effects, and drug interactions must be kept in mind while choosing the appropriate anti-obesity medication for a particular patient.

Competitive Landscape

The major global players in the weight loss therapeutics market include F Hoffmann-la Roche Ltd, Currax Pharmaceuticals LLC, Viking Therapeutics, Pfizer Inc., Eli Lilly and Company, Altimmune, VIVUS LLC, Rhythm Pharmaceuticals, Amgen Inc. and Zealand Pharma A/S among others.

Company Name: DataM Intelligence
Contact Person: Sai.K
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website:https://www.datamintelligence.com/

DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.